Courses

Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 1 & 2

Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 1 & 2

This CME program will highlight evidence based dietary and pharmacologic approaches to manage patients with hyperkalemia. Starting with module 1, Dr. Biff Palmer will review the science of recurrent hyperkalemia, including relationships between dietary potassium intake, serum potassium, and patient morbidities. Next, in module 2, Dr. Pamela Kushner will evaluate the limitations and impact of plant-based diets and potassium restricted ...
View Course

The Role of Neonatal Fc Receptor (FcRn) Blocking Therapeutics in the Management of Patients with Generalized Myasthenia Gravis

The Role of Neonatal Fc Receptor (FcRn) Blocking Therapeutics in the Management of Patients with Generalized Myasthenia Gravis

This CME program will highlight recent advances in the treatment and management of patients with myasthenia gravis (MG). The expert faculty, Dr. James F. Howard Jr., will first outline the pathophysiology and disease course of MG, referencing the impact of treatment and disease burden on patients. Following, current clinical trial data, including that of complement inhibitor therapies in generalized myasthenia ...
View Course
Update on Best Practices for the Prompt and Personalized Management of Patients with COPD Exacerbations

Update on Best Practices for the Prompt and Personalized Management of Patients with COPD Exacerbations

This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. William Corrao, will first highlight strategies for early diagnosis and classification of chronic obstructive pulmonary disease (COPD), referencing the current Gold Guidelines. Following, current clinical trial data will be reviewed, and clinical relevance debated in an interactive panel format. Dr. Corrao will ...
View Course
Advances in the Diagnosis and Management of Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE): The Role of Dipeptidyl Peptidase 1 (DPP1) Inhibitor Therapeutics

Advances in the Diagnosis and Management of Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE): The Role of Dipeptidyl Peptidase 1 (DPP1) Inhibitor Therapeutics

This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. Gregory Tino, will first outline the pathophysiology, prevalence and radiological distribution of non-cystic fibrosis bronchiectasis (NCFBE). Current treatment guidelines and recommendations for patients with NCFBE will be reviewed and an overview of phenotyping provided. Dr. Tino will conclude with an analysis of ...
View Course
Advances in the Diagnosis and Management of Patients with Non-Tuberculin Mycobacterial Lung Disease: The Role of Amikacin-Based Inhalation Therapeutics

Advances in the Diagnosis and Management of Patients with Non-Tuberculin Mycobacterial Lung Disease: The Role of Amikacin-Based Inhalation Therapeutics

This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. Anne O’Donnell, will first outline both the prevalence and pathophysiology of non-tuberculin mycobacterial lung disease (NTM-LD). Following, current clinical trial data for mycobacterium avium complex (MAC) will be reviewed and clinical relevance debated, including a conversation of toxicities and challenges for clinicians ...
View Course
An Update on the Assessment and Therapeutic Management of Cognitive Decline in Patients with Multiple Sclerosis

An Update on the Assessment and Therapeutic Management of Cognitive Decline in Patients with Multiple Sclerosis

This CME program will provide an update on the assessment and therapeutic management of cognitive decline in patients with multiple sclerosis (MS). The expert faculty, Dr. Ann Bass, will first cover multiple sclerosis cognition dysfunction in the modern treatment era, highlighting various measurement tools. Following, recent clinical trial data regarding treatment and prevention of cognitive decline will be reviewed, including ...
View Course
Treatment Strategies for Basal Insulins to Manage Time-in-Range and Glucose Variability to Improve Outcomes in Patients with Diabetes

Treatment Strategies for Basal Insulins to Manage Time-in-Range and Glucose Variability to Improve Outcomes in Patients with Diabetes

This CME/CE program will provide clinicians with an update on treatment strategies for basal insulins to manage time-in-range and glucose variability to improve outcomes in patients with diabetes. The expert faculty will review the importance of the role of the diabetes care and education specialist to minimize glucose variability in patients on longer-acting insulins. Next, a clinical review of newer longer-acting ...
View Course

Treatment Strategies for Basal Insulins to Manage Time-in-Range and Glucose Variability to Improve Outcomes in Patients with Diabetes

Treatment Strategies for Basal Insulins to Manage Time-in-Range and Glucose Variability to Improve Outcomes in Patients with Diabetes

This CME program will highlight treatment strategies for basal insulins to manage time-in-range and glucose variability to improve outcomes in patients with diabetes. The expert faculty, Dr. Neil S. Skolnik, will outline the importance of improving patients’ glucose to time-in-range, minimize glucose variability, and incorporate continuous glucose monitoring in patients with diabetes. Following, Dr. Skolnik will discuss how to distinguish ...
View Course

Update on the Safety and Efficacy of JAK Inhibitor Therapeutics for the Treatment of Atopic Dermatitis

Update on the Safety and Efficacy of JAK Inhibitor Therapeutics for the Treatment of Atopic Dermatitis

This CME program will provide clinicians with an update regarding the safety and efficacy of JAK inhibitor therapeutics for the treatment of atopic dermatitis. The expert faculty, led by Dr. Lawrence F. Eichenfield, will first outline current clinical trial data for JAK-1 inhibitor therapeutics in atopic dermatitis (AD), encompassing topics such as difficulties living with AD and the unmet needs ...
View Course
The Impact of the COVID Pandemic on Continuity of Care and Adherence to DAPT Among Patients with CAD/ACS/PCI

The Impact of the COVID Pandemic on Continuity of Care and Adherence to DAPT Among Patients with CAD/ACS/PCI

Areas of North America and Western Europe have struggled with repeated waves and emerging variants of SARS CoV-2 infection. Even as some countries and regions strive to return to pre-pandemic behavior, the COVID-19 pandemic continues to exert many deleterious effects on the delivery of continuing healthcare for many vulnerable populations. Those affected include patients who would be expected to benefit ...
View Course